The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the possibility for game-changing treatments and substantial returns is clear, the connected risks are also considerable. Many